Boston Life Sciences, Inc. Announces the Issuance of a U.S. Patent Licensed to BLSI by Harvard et al that Covers Methods for th
August 10 2006 - 4:46PM
PR Newswire (US)
Methods Encompass Current Imaging Techniques Using Labeled Dopamine
Transporter Binding Compounds HOPKINTON, Mass., Aug. 10
/PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSI)
announces that the U.S. Patent and Trademark Office has issued a
patent to the President and Fellows of Harvard College, the General
Hospital Corporation and Organix, Inc. that covers methods of
diagnosing and monitoring attention deficit hyperactivity disorder
(ADHD) by assessing the level of dopamine transporter (DAT) in at
least one region of a patient's central nervous system. The patent
is exclusively licensed to BLSI under a worldwide licensing
arrangement between BLSI and Harvard University. The patent is
based on the work of the inventors, Dr. Bertha Madras of Harvard,
Dr. Peter Meltzer of Organix, Inc., and Dr. Alan Fischman of
Massachusetts General Hospital. Both Dr. Fischman and Dr. Meltzer
serve as advisors to BLSI. The patent claims a variety of
diagnostic and monitoring methods for assessing ADHD utilizing
labeled compounds that bind to the dopamine transporter and are
measured using any imaging technique including single photon
emission computed tomography (SPECT) and positron emission
tomography (PET). An example of a compound covered by the patent is
the Company's ALTROPANE(R) molecular imaging agent currently in
Phase II clinical trials as an aid to ADHD diagnosis. The Company
is currently analyzing imaging results and clinical data, both of
which were obtained from patients enrolled to-date, to verify
findings in prior studies and ensure that the trial design and
quantification algorithms are appropriate. In addition to methods
used to objectively diagnose ADHD in adults or children, the patent
covers methods that could enable physicians to determine the most
effective ADHD drug treatment and/or dosage level for an individual
patient, monitor the long-term progress of treatment for ADHD, and
aid in identifying individuals at risk for ADHD. Mark Hurtt, BLSI's
Chief Medical Officer, comments, "The use of imaging techniques and
dopamine transporter specific imaging agents has the potential to
provide an objective, biologically-based diagnosis for ADHD. We are
very pleased with the potential scope of this patent. We believe
that the new patent enhances our position in this significant area
of medical need. According to the Centers for Disease Control,
between 3% and 7% of school-aged children and 2 to 4% of adults
have been diagnosed with ADHD. We believe that imaging agents may
assist physicians in confirming a diagnosis, resolving conflicting
diagnoses, calling into question a diagnosis or non-diagnosis of
ADHD, or selecting medication." About the Patent The new patent
issued on July 25, 2006 under U.S. patent number 7,081,238 B2. The
application was filed on August 17, 2001 and, under 35 U.S.C.
154(b) had 142 days added to its duration. About ADHD According to
the Center for Disease Control, Attention Deficit Hyperactivity
Disorder (ADHD) is one of the most common neurobehavioral disorders
of childhood and can persist through adolescence and into
adulthood. ADHD affects almost 4 million school-aged children and
is among the fastest growing neurobehavioral disorders in adults
with an estimated 2-4% of Americans affected. ADHD is now diagnosed
by medical and mental health professionals with a set of behavioral
criteria but there is currently no objective biological test. About
BLSI Boston Life Sciences, Inc. (BLSI) is engaged in the research
and clinical development of diagnostic and therapeutic products for
central nervous system (CNS) disorders. ALTROPANE(R) molecular
imaging agent is in Phase III clinical trials for the diagnosis of
Parkinsonian Syndrome (PS) and in Phase II clinical trials for the
diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The
Company's research and pre-clinical CNS programs include INOSINE
for the treatment of stroke, a DAT blocker for the treatment of
Parkinson's disease and a second generation technetium-based
molecular imaging agent for PS and ADHD. BLSI's current research
collaborations include Harvard Medical School and Children's
Hospital Boston. Safe Harbor The foregoing release contains certain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward- looking
statements include statements regarding Boston Life Sciences'
future expectations, beliefs, intentions, goals, strategies, plans
or prospects regarding the future, including the Company's current
and future programs relating to ADHD, licensing arrangements by the
Company for certain intellectual property, and the scope of, the
methods covered by, uses and potential uses of such intellectual
property. Forward-looking statements can be identified by
terminology such as "anticipate," "believe," "could," "could
increase the likelihood," "estimate," "expect," "intend," "is
planned," "may," "should," "will," "will enable," "would be
expected," "look forward," "may provide," "would" or similar terms,
variations of such terms or the negative of those terms. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors including those risks,
uncertainties and factors referred to in the Company's Quarterly
Report on Form 10-Q for the quarter ended March 31, 2006 filed with
the Securities and Exchange Commission under the section "Risk
Factors," as well as other documents that may be filed by Boston
Life Sciences from time to time with the Securities and Exchange
Commission. As a result of such risks, uncertainties and factors,
the Company's actual results may differ materially from any future
results, performance or achievements discussed in or implied by the
forward-looking statements contained herein. Boston Life Sciences
is providing the information in this press release as of this date
and assumes no obligations to update the information in this press
release. Contact: Sharon Correia -- 508-497-2360 ext 224 Boston
Life Sciences, Inc. DATASOURCE: Boston Life Sciences, Inc. CONTACT:
Sharon Correia, +1-508-497-2360, ext. 224 of Boston Life Sciences,
Inc., Web site: http://www.bostonlifesciences.com/
Copyright
Boston Life Sciences (NASDAQ:BLSI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Boston Life Sciences (NASDAQ:BLSI)
Historical Stock Chart
From Oct 2023 to Oct 2024